Colorectal cancer and non-steroidal anti-inflammatory drugs

Acta Pharmacologica Sinica

Volumn 21, Issue 5, 2000, Pages 391-395

  Ota, Shinichi ^a   Bamba, Hiromi ^b   Kato, Akira ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenoma; Colonic neoplasms; Non steroidal anti inflammatory agents; Prostaglandin; Prostaglandin endoperoxide synthase

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; INDOMETACIN; KETOPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SULINDAC;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON ADENOMA; COLON CARCINOGENESIS; COLORECTAL CANCER; DRUG MECHANISM; FAMILIAL COLON POLYPOSIS; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RAT;

ADENOCARCINOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0034067160     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Kudo T, Narisawa T, Abo S. Anti-tumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 1980; 71: 260-4.
2. Smalley W, Dubois RN. Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1-20.
3. Shiff SJ, Basil R. Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions. Gastroenterology 1997; 113: 1992-8.
4. Giardielo FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl J Med 1993; 328: 1313-6.
5. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of colon cancer. N Engl J Med 1991; 325: 1593-96.
6. Peleg II, Maiboch HT, Brown SH, Wilcox CM. Aspirin and non-steroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Int Med 1991; 154: 394-9.
7. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171-7.
8. Gridley G, Meloughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307-11.
9. Schreinemacher DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1991; 5: 138-46.
10. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic disease: a cohort study of elderly. Br Med J 1989; 229: 1247-50.
11. Giovanucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Int Med 1994; 121: 241-6.
12. Thun MJ, Namboodiri MM, Calle EE, Randers WD, Heath CW Jr. Aspirin use and the risk of fatal cancer. Cancer Res 1993; 53: 1322-7.
13. Dubois RN, Giardiello FM, Smalley WE. Nonsteroidal sntiinflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterology clinics of North America 1996; 25: 773-91.
14. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C. Multiple intestinal neoplasia caused by a mutation in the murine homologue of the APC gene. Science 1992; 256: 668-70.
15. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, et al. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the non-steroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56: 710-4.
16. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-12.
17. Yoshimi N, Kawabata K, Hara A, Matsunaga K, Yamada Y, Mon H. Inhibitory effect of NS-398, a selective cyclooxygenase inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res 1997; 88: 1014-51.
18. Yoshimi N, Shimizu M, Matsunaga K, Yamada Y, Fujii K, Hara A, et al. Chemopreventive effect of N-(2-cyclohexy-4-nitrophenyl) methanesulfonamide (NS-398), a selective cyclooxygenase inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 1999; 90: 406-12.
19. Fukutake M, Nakatsugi S, Isoi T, Takahashi M, Ohta T, Mamiya. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon-carcinogenesis in mice. Carcinogenesis 1998; 19: 1939-42.
20. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9.
21. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutation occur early during colorectal tumorigenesis. Nature 1992; 359: 235-7.
22. Waddel WR, Laughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-7.
23. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effect of long-term sulindac therapy on colonic polyposis. Ann Int Med 1991; 115: 952-4.
24. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized control trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618-19.
25. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. SAID effect on sporadic colon polyps. Am J Gastroenterology 1993; 88: 1652-6.
26. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, et al. Effects of sulindac on sporadic colonic polyps. Gastroenterology 1995; 108: 1083-7.
27. Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1977; 40: 314-9.
28. Matsuhashi N, Nakajima A, Shinohara K, Oka T, Yazaki Y. Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp. Am J Gastroenterology 1998; 93: 2261-6.
29. Sandier RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and non-steroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998; 114: 441-7.
30. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
31. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-9.
32. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and 2 protein in human colon cancer. Cancer Res 1995; 55: 2556-9.
33. Dubois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110: 1252-62.
34. Williams CS, Luongo C, Radhika AA, Zhang T, Lamps LW, Nanney LB, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111: 1134-40.
35. Hull Ma, Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF, et al. Cyclooxygenase-2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999; 79: 1399-405.
36. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999; 83: 470-5.
37. Krutzush M, Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55: 3310-6.
38. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon cells. J Clin Invest 1995; 96: 491-503.
39. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying non-steroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA. 1998; 95: 681-6.
40. Tsujii M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
41. Elder DJE, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drug: independence from COX-2 protein expression . Clin Cancer Res 1997; 3: 1679-83.
42. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al. Effects of non-steroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-45.
43. 2 in human colon cancer cells. Cancer Res 1998; 58: 362-6.
44. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89.
45. Hong W, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278: 1073-7.
46. Takahashi M, Ota S, Hata Y, Mikami Y, Azuma N, Nakamura T, et al. Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach. J Clin Invest 1996; 98: 2601-11.
47. Bamba H, Ota S, Kato A, Matsuzaki F. Nonsteroidal antiinflammatory drugs may delay the repair of gastric mucosa by suppressing prostaglandin-mediated increase of hepatocyte growth factor production. Biochem Biophys Res Commun 1998; 245: 567-71.
48. Ota S, Tanaka Y, Bamba H, Kato A, Matsuzaki F. Nonsteroidal anti-inflammatory drugs may prevent colon cancer through suppression of hepatocyte growth factor expression. Eur J Pharmacol 1999; 367: 131-8.